CureVac

CureVac, a global biopharmaceutical company, is a leader in messenger RNA (mRNA) technology, with over 20 years of experience in developing and manufacturing this versatile biological molecule for medical purposes. Its proprietary technology uses optimized mRNA as a data carrier to instruct the human body to produce proteins to combat various diseases. In 2020, CureVac initiated a collaboration with GSK to develop new products in prophylactic vaccines based on its second-generation mRNA technology. Later, the collaboration expanded to include the development of second-generation COVID-19 vaccine candidates and modified mRNA vaccine technologies. With its headquarters in Tübingen, Germany, CureVac has over 1,100 employees across sites in Germany, the Netherlands, Belgium, Switzerland, and the U.S. The company focuses on areas such as prophylactic vaccines, cancer therapies, antibody therapies, and rare disease treatments. Recently, CureVac secured a significant $250.00M Post-IPO Equity investment in February 2023. This investment signals confidence in CureVac's innovative approach to mRNA technology and the potential of its clinical pipeline. As a leader in the biopharma and biotechnology industries, CureVac continues to make strides in developing impactful medical solutions. The company's strategic collaboration with a renowned partner like GSK further adds credibility to its growth trajectory. With its strong foothold in Europe and the U.S., CureVac is poised to drive advancements in mRNA-based therapies and vaccines, offering promising prospects for investors interested in the healthcare and biopharmaceutical sectors. For more information about CureVac, visit www.curevac.com.